NasdaqGS:RAREBiotechs
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After FDA Priority Review For DTX401
Ultragenyx Pharmaceutical (RARE) is back in focus after the U.S. FDA accepted its Biologics License Application for DTX401, a gene therapy candidate for Glycogen Storage Disease Type Ia, and granted it Priority Review.
See our latest analysis for Ultragenyx Pharmaceutical.
The FDA Priority Review comes after a volatile period for Ultragenyx, with the latest share price at $22.51 and a 7-day share price return of 9.7% contrasting with a 90-day share price return of a 32.9% decline and a 1-year...